Bioventus Inc. Class A Common Stock (BVS) Stock
Key stats
- Market cap
- $752.53M
- Price / Earnings ratio
- 16.4x
- EPS (TTM)
- $0.85
- Volume
- Loading
- 52-week high
- $15.89
- 52-week low
- $6.47
Source: third-party data provider, as of November 13, 2026
Compare with BVS
Recent news

Bioventus (BVS) Matches Q3 Earnings Estimates
Bioventus (BVS) Matches Q3 Earnings Estimates
BVS

Bioventus Q3 Earnings Call Highlights
Bioventus Q3 Earnings Call Highlights
BVS

Are Medical Stocks Lagging Bioventus (BVS) This Year?
Are Medical Stocks Lagging Bioventus (BVS) This Year?
BVS

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
BVS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 34.87
- MACD 12/26/9
- -0.74
- EMA 9 of MACD
- -0.42
- MACD histogram
- -0.32
- SMA 50
- $13.28
- Price below SMA 50
- EMA 50
- $12.95
- Price below EMA 50
- SMA 200
- $11.03
- Price below SMA 200
- EMA 200
- $11.03
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Bioventus (BVS) Matches Q3 Earnings Estimates
Bioventus (BVS) Matches Q3 Earnings Estimates
BVS

Bioventus Q3 Earnings Call Highlights
Bioventus Q3 Earnings Call Highlights
BVS

Are Medical Stocks Lagging Bioventus (BVS) This Year?
Are Medical Stocks Lagging Bioventus (BVS) This Year?
BVS

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
BVS

Is Bioventus (BVS) Stock Undervalued Right Now?
Is Bioventus (BVS) Stock Undervalued Right Now?
BVS

Bioventus Q2 Earnings Call Highlights
Bioventus Q2 Earnings Call Highlights
BVS

Bioventus (BVS) Q2 Earnings Meet Estimates
Bioventus (BVS) Q2 Earnings Meet Estimates
BVS

Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth
BVS

Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
BVS

Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
BVS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Bioventus Inc. Class A Common Stock
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert E. Claypoole | President, CEO & Director | 1972 |
| Mr. Mark L. Singleton | Senior VP & CFO | 1969 |
| Mr. Anthony D'Adamio J.D. | Senior VP, General Counsel & Corporate Secretary | 1961 |
| Mr. Mike Crowe B.S., M.B.A. | Senior Vice President of Operations | — |
| Mr. David Crawford | Vice President of Investor Relations & Treasurer | — |
| Ms. Katrina J. Church J.D. | Senior VP & Chief Compliance Officer | 1962 |
| Ms. Helen Leupold | Senior VP & Chief Human Resources Officer | — |
| Mr. Dave Venner | Senior VP & GM of Surgical | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 34.87
- MACD 12/26/9
- -0.74
- EMA 9 of MACD
- -0.42
- MACD histogram
- -0.32
- SMA 50
- $13.28
- Price below SMA 50
- EMA 50
- $12.95
- Price below EMA 50
- SMA 200
- $11.03
- Price below SMA 200
- EMA 200
- $11.03
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $15.00
- Average
- $16.50
- High
- $18.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.4 | -15.8 | +19.0 | +33.7 | +1.3 | -0.3 | -0.9 | -16.4 |



